Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: -0.10 (-5.71%)
Spread: 0.10 (6.25%)
Open: 1.75
High: 1.90
Low: 1.625
Prev. Close: 1.75
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (DD) - Shield Therapeutics Plc

5 May 2023 15:09

RNS Number : 6300Y
finnCap
05 May 2023
 

These transactions have taken place as a consequence of book flattening. The Panel Executive has informed finnCap Ltd on an ex parte basis that such transactions are permitted and have no Code consequences.

 

FORM 8 (DD)

 

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

finnCap Ltd

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shield Therapeutics Plc

(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

Joint broker to offeree Shield Therapeutics Plc

(e) Date dealing undertaken:

04/05/2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 

Class of relevant security:

 

Ordinary GBP 1.5P

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

 

Nil

 

(2) Cash-settled derivatives:

 

Nil

 

Nil

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

 

Nil

 

 

TOTAL:

Nil

 

Nil

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary GBP 0.015

PURCHASE

 

70,966

7.5 pence

 

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

05/05/2023

Contact name:

Mark Tubby

Telephone number:

+44 (0) 20 7220 0504

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DCCZELFBXELBBBE
Date   Source Headline
30th Apr 20247:00 amRNSBusiness Update for Q1 2024
16th Apr 20247:00 amRNSNotice of Results
21st Feb 20247:00 amRNSUnaudited Full Year Trading Update
9th Jan 20247:00 amRNSAppointment of new Chief Financial Officer
7th Dec 20237:00 amRNSQ3 2023 U.S. Commercial Highlights
27th Nov 20235:24 pmRNSPDMR Transaction Notification
15th Nov 20237:30 amEQSHardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team
20th Oct 202311:45 amRNSAbstract to be presented at Healthcare Conference
12th Oct 20237:00 amRNSChief Financial Officer Transition
3rd Oct 20233:00 pmRNSResult of REX Retail Offer
3rd Oct 20237:00 amRNSBlock listing Interim Return
3rd Oct 20237:00 amRNSCompletion of SWK Financing
28th Sep 202312:50 pmRNSSuccessful completion of US$6.1m Equity Fundraise
28th Sep 20237:02 amRNSREX Retail Offer
28th Sep 20237:01 amRNS$20m secured debt facility &proposed equity raise
28th Sep 20237:00 amRNSInterim results update and business update
6th Sep 20237:00 amRNSNotice of Results and Change in reporting currency
25th Jul 20239:45 amEQSHardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
24th Jul 20232:27 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSBusiness Update and U.S. Q2 2023 Highlights
28th Jun 20235:30 pmRNSResults of 2023 Annual General Meeting
16th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
15th Jun 20234:35 pmRNSLapse of Offer
15th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
15th Jun 20237:00 amRNSAcceptance Level Update
14th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
14th Jun 20237:00 amRNSAcceptance Level Update
13th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
13th Jun 20237:00 amRNSAcceptance Level Update
12th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
12th Jun 20237:00 amRNSAcceptance Level Update
9th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th Jun 20237:00 amRNSAcceptance Level Update
8th Jun 202312:31 pmRNSForm 8.3 - Shield Therapeutics PLC (amendment)
8th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
8th Jun 20237:00 amRNSAcceptance Level Update
7th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
6th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
6th Jun 202310:10 amRNSGrant of share options to the CEO
5th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
2nd Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
1st Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
1st Jun 202311:00 amRNSHolding(s) in Company
1st Jun 202310:55 amRNSHolding(s) in Company
31st May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
31st May 20237:00 amRNSTotal Voting Rights
30th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
26th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
25th May 20234:44 pmRNSPublication and posting of Offer Document
25th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.